TY - JOUR
T1 - COPD Pathogenesis
T2 - Finding the Common in the Complex
AU - Cantor, Jerome O.
AU - Turino, Gerard M.
N1 - Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following: J. C. and G. T. have a financial interest in MatRx Therapeutics, which is developing nebulized HA as a treatment for COPD.
Publisher Copyright:
© 2018 American College of Chest Physicians
PY - 2019/2
Y1 - 2019/2
N2 - Developing an effective treatment for COPD, and especially pulmonary emphysema, will require an understanding of how fundamental changes at the molecular level affect the macroscopic structure of the lung. Currently, there is no accepted model that encompasses the biochemical and mechanical processes responsible for pulmonary airspace enlargement. We propose that pulmonary emphysematous changes may be more accurately described as an emergent phenomenon, involving alterations at the molecular level that eventually reach a critical structural threshold where uneven mechanical forces produce alveolar wall rupture, accompanied by advanced clinical signs of COPD. The coupling of emergent morphologic changes with biomarkers to detect the process, and counteract it therapeutically, represents a practical approach to the disease.
AB - Developing an effective treatment for COPD, and especially pulmonary emphysema, will require an understanding of how fundamental changes at the molecular level affect the macroscopic structure of the lung. Currently, there is no accepted model that encompasses the biochemical and mechanical processes responsible for pulmonary airspace enlargement. We propose that pulmonary emphysematous changes may be more accurately described as an emergent phenomenon, involving alterations at the molecular level that eventually reach a critical structural threshold where uneven mechanical forces produce alveolar wall rupture, accompanied by advanced clinical signs of COPD. The coupling of emergent morphologic changes with biomarkers to detect the process, and counteract it therapeutically, represents a practical approach to the disease.
UR - http://www.scopus.com/inward/record.url?scp=85053844384&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2018.07.030
DO - 10.1016/j.chest.2018.07.030
M3 - Article
C2 - 30080996
AN - SCOPUS:85053844384
SN - 0012-3692
VL - 155
SP - 266
EP - 271
JO - Chest
JF - Chest
IS - 2
ER -